BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 120 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3 | 0.0% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2024 | $3 | 0.0% | 500 | 0.0% | 0.00% | -50.0% |
| Q4 2023 | $3 | -25.0% | 500 | 0.0% | 0.00% | -33.3% |
| Q3 2023 | $4 | 0.0% | 500 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $4 | 0.0% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $4 | -33.3% | 500 | 0.0% | 0.00% | -25.0% |
| Q4 2022 | $6 | -99.9% | 500 | 0.0% | 0.00% | -20.0% |
| Q3 2022 | $6,000 | +20.0% | 500 | 0.0% | 0.01% | +25.0% |
| Q2 2022 | $5,000 | -37.5% | 500 | 0.0% | 0.00% | -20.0% |
| Q1 2022 | $8,000 | +14.3% | 500 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $7,000 | 0.0% | 500 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $7,000 | -12.5% | 500 | 0.0% | 0.01% | -16.7% |
| Q2 2021 | $8,000 | +60.0% | 500 | 0.0% | 0.01% | +50.0% |
| Q1 2021 | $5,000 | +25.0% | 500 | 0.0% | 0.00% | +33.3% |
| Q4 2020 | $4,000 | +100.0% | 500 | 0.0% | 0.00% | +50.0% |
| Q3 2020 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $2,000 | +100.0% | 500 | 0.0% | 0.00% | +100.0% |
| Q1 2020 | $1,000 | -50.0% | 500 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $2,000 | +100.0% | 500 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $1,000 | -50.0% | 500 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $2,000 | -50.0% | 500 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $4,000 | 0.0% | 500 | 0.0% | 0.00% | -25.0% |
| Q4 2018 | $4,000 | 0.0% | 500 | 0.0% | 0.00% | +33.3% |
| Q3 2018 | $4,000 | +33.3% | 500 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $3,000 | -99.9% | 500 | 0.0% | 0.00% | +50.0% |
| Q1 2018 | $2,385,000 | -2.9% | 500 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $2,455,000 | -6.3% | 500 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,620,000 | -5.8% | 500 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $2,780,000 | -33.8% | 500 | 0.0% | 0.00% | -50.0% |
| Q1 2017 | $4,200,000 | +32.7% | 500 | 0.0% | 0.00% | +33.3% |
| Q4 2016 | $3,165,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |